Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24218522 | 0.91 | HDAC3 (0.65) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL8170991 | 0.81 | DNM1 (0.48) | DNM1PAOXPHF8KDM2AKDM4A | |
| SCHEMBL964918 | 0.79 | CTSD (0.50) | DNM1PAOXPHF8KDM2AKDM4E | |
| SCHEMBL16293640 | 0.77 | DNM1 (0.59) | DNM1PAOXPHF8KDM2AKDM4A | |
| SCHEMBL8773743 | 0.77 | DNM1 (0.76) | DNM1PAOXKDM4E | |
| SCHEMBL29076197 | 0.77 | DNM1 (0.46) | DNM1PAOXPHF8KDM2AKDM4A | |
| SCHEMBL11768749 | 0.76 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Glutarodihydroxamic Acid SCHEMBL11768782 | 0.76 | HDAC1 (0.81) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL7721282 | 0.76 | MEN1 (0.57) | DNM1PAOXPHF8KDM2AKDM4E | |
| SCHEMBL26484642 | 0.74 | DNM1 (0.52) | DNM1PAOXPHF8KDM2AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4114375-A1 | FERROPTOSIS INHIBITORS-DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd (KY) | 2023-01-11 | — | — | EP | disclosed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | HDAC1 819/4885HDAC3 970/4885HDAC2 746/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | HDAC1 1103/4885HDAC3 1210/4885HDAC2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.